menu
    • menu

    Company profile for SciNeuro Pharmaceuticals

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are building an integrated team of scientists, clinicians and business leaders who bring deep expertise and experience from the pharma & biotech industry and clinical science. We are committed to establishing a broad network of academic and industry collaborators, with whom we partner to deliver new medicines to patients in need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SciNeuro PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    9605 Medical Center Dr Ste 230, Rockville, Maryland, 20850, United States
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://scineuro.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/scineuro-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/PharmaNeuro

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis Makes $1.5B+ Alzheimer's Play With China's Scineuro
    Novartis Makes $1.5B+ Alzheimer's Play With China's Scineuro

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/scineuro-and-novartis-enter-into-a-licensing-and-collaboration-agreement-for-next-generation-therapeutics-to-treat-alzheimers-disease-302658400.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Scineuro Raises $53M for Neurodegenerative Pipeline, Names CFO
    Scineuro Raises $53M for Neurodegenerative Pipeline, Names CFO

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/scineuro-pharmaceuticals-announces-53-million-financing-to-further-advance-pipeline-of-therapies-for-neurodegenerative-diseases-and-appointment-of-chief-financial-officer-302632639.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor
    SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor

    12 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/scineuro-initiates-phase-1-clinical-trial-with-snp318-a-novel-lp-pla2-inhibitor-targeting-neurodegenerative-and-inflammatory-diseases-301795215.html

    PR NEWSWIRE
    12 Apr 2023
    Share Share
    SciNeuro Pharma Announces the Appointment of Guojun Bu, Ph.D., as CSO
    SciNeuro Pharma Announces the Appointment of Guojun Bu, Ph.D., as CSO

    02 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/scineuro-pharmaceuticals-announces-the-appointment-of-guojun-bu-phd-as-chief-scientific-officer-and-provides-update-on-pipeline-of-novel-cns-therapeutics-301692283.html

    PRNEWSWIRE
    02 Dec 2022
    Share Share
    SciNeuro Pharma Announces License and Option Agreement with GSK for CNS Diseases
    SciNeuro Pharma Announces License and Option Agreement with GSK for CNS Diseases

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/scineuro-pharmaceuticals-announces-a-license-and-option-agreement-with-gsk-to-progress-development-of-novel-therapies-for-cns-diseases-301557923.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    SciNeuro and Mabylon Collaborate to develop therapy for Neurological Diseases
    SciNeuro and Mabylon Collaborate to develop therapy for Neurological Diseases

    26 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211026005282/en

    BUSINESSWIRE
    26 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search